Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 3692
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2006  |  Volume : 54  |  Issue : 4  |  Page : 241-245

The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis


1 Firat University School of Medicine, Department of Ophthalmology, Elazig, Turkey
2 Firat University School of Medicine, Department of Immunology, Elazig, Turkey

Correspondence Address:
Peykan Türkçüoglu
Firat University School of Medicine, Department of Ophthalmology, Elazig
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.27948

Rights and Permissions

Background: To identify the effect of infliximab, cyclosporine A and recombinant IL-10 in experimental autoimmune uveitis. Materials and Methods: Sixty male rats were assigned to five groups of 12 each. All the groups (except the control group) were administered 30 µg retinal-S antigen intraperitoneally. On the 14th day, after confirmation of uveitis with histopathological study, daily cyclosporine A injection was given in cyclosporine A treatment group and physiological serum in the uveitis-induced placebo treatment and control groups. In the infliximab treatment group, infliximab was administered on the 14th, 15th, 17th, 19th and 21st days. In the recombinant IL-10 treatment group, three doses of recombinant IL-10 were given four hours and a half hours before and eight hours after retinal-S antigen administration. On the 21st day of the study, all rats were sacrificed and vitreous cytokine levels (IL-1, IL-6, IL-8 and TNF-a) were studied with ELISA. Results: In the treatment groups, cytokine levels (IL-1, IL-6 and TNF-a) were significantly lower than the uveitis-induced placebo treatment group. Compared with the control group, there was no significant difference with respect to TNF-a and IL-8 in the infliximab treatment group; IL-8 in the cyclosporine A treatment group; IL-6 and IL-8 in the recombinant IL-10 treatment group. The drugs used did not significantly differ in respect to their effects on vitreous IL-6, IL-8 and TNF-a levels. Conclusion: Cyclosporine A, infliximab and recombinant IL-10 reduce the vitreous cytokines levels. Among these drugs, recombinant IL-10, which is still in its experimental phase, might be considered as a new therapeutic agent.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4916    
    Printed128    
    Emailed2    
    PDF Downloaded515    
    Comments [Add]    
    Cited by others 12    

Recommend this journal